5IJD image
Entry Detail
PDB ID:
5IJD
Keywords:
Title:
The crystal structure of mouse TLR4/MD-2/lipid A complex
Biological Source:
Host Organism:
PDB Version:
Deposition Date:
2016-03-01
Release Date:
2016-04-27
Method Details:
Experimental Method:
Resolution:
2.70 Å
R-Value Free:
0.28
R-Value Work:
0.21
R-Value Observed:
0.21
Space Group:
P 1 21 1
Macromolecular Entities
Polymer Type:polypeptide(L)
Description:Toll-like receptor 4, Variable lymphocyte receptor B chimera
Chain IDs:A, D (auth: B)
Chain Length:594
Number of Molecules:2
Biological Source:Mus musculus, Eptatretus burgeri
Polymer Type:polypeptide(L)
Description:Lymphocyte antigen 96
Chain IDs:B (auth: C), C (auth: D)
Chain Length:150
Number of Molecules:2
Biological Source:Mus musculus
Modified Residue
Compound ID Chain ID Parent Comp ID Details 2D Image
NAG E NAG -D
Primary Citation
TLR4/MD-2 activation by a synthetic agonist with no similarity to LPS.
Proc.Natl.Acad.Sci.USA 113 E884 E893 (2016)
PMID: 26831104 DOI: 10.1073/pnas.1525639113

Abstact

Structurally disparate molecules reportedly engage and activate Toll-like receptor (TLR) 4 and other TLRs, yet the interactions that mediate binding and activation by dissimilar ligands remain unknown. We describe Neoseptins, chemically synthesized peptidomimetics that bear no structural similarity to the established TLR4 ligand, lipopolysaccharide (LPS), but productively engage the mouse TLR4 (mTLR4)/myeloid differentiation factor 2 (MD-2) complex. Neoseptin-3 activates mTLR4/MD-2 independently of CD14 and triggers canonical myeloid differentiation primary response gene 88 (MyD88)- and Toll-interleukin 1 receptor (TIR) domain-containing adaptor inducing IFN-beta (TRIF)-dependent signaling. The crystal structure mTLR4/MD-2/Neoseptin-3 at 2.57-Å resolution reveals that Neoseptin-3 binds as an asymmetrical dimer within the hydrophobic pocket of MD-2, inducing an active receptor complex similar to that induced by lipid A. However, Neoseptin-3 and lipid A form dissimilar molecular contacts to achieve receptor activation; hence strong TLR4/MD-2 agonists need not mimic LPS.

Legend

Protein

Chemical

Disease

Primary Citation of related structures